Rhabdomyosarcoma (RMS) is a relatively rare soft tissue malignancy that can arise at any age, with approximately 600 new cases diagnosed per year in the United States, 41% of which occur in adults versus 59% in children 1 . Statistically, RMS is uncommon in adults, with soft tissue sarcomas comprising less than 1% of all malignancies, 3% of which are RMS 2 . By contrast, soft tissue sarcomas account for 10% of all childhood malignancies, 50% of which are RMS 3 ; thus, RMS is a well-known clinical problem in paediatric oncology. Even when rendered disease-free, RMS survivors often experience long-term morbidities owing to intensive multimodal therapy, with paediatric patients in particular enduring a lifetime risk for treatment-related secondary malignancies. Treatments for high-risk RMS (BOX 1) have not improved for three decades, underscoring the need to elucidate the molecular mechanisms of the disease.
These neoplasms demonstrate complex karyotypes, but with no recurrent structural alterations. They are highly aggressive, and the majority metastasize within 5 years of diagnosis.
Spindle cell/sclerosing RMS 7 is comparatively uncommon, but affects both children and adults. In children, these tumours are predominantly paratesticular, whereas in adults they are typically found in the deep soft tissues of the head and neck. Spindle cell/sclerosing RMS has varied genetic and clinical features, with congenital and infantile spindle cell RMS harbouring nuclear receptor co-activator 2 (NCOA2) gene rearrangements 8 and a favourable prognosis, whereas a subset of spindle cell/sclerosing RMS in older children and adults show recurrent mutations in myogenic differentiation 1 (MYOD1) 9, 10 , which portends a poor prognosis. Alveolar RMS (ARMS) 5 is also notoriously aggressive, occurring more frequently in adolescents and young adults, and typically associates with pathognomonic chromosomal translocations, t(2;13)(q35;q14) or t(1;13) (p36;q14), which account for 60% or 20% of ARMS cases, respectively. Both translocations fuse a paired box (PAX) gene (PAX3 on chromosome 2 or PAX7 on chromosome 1) to the 3ʹ end of the forkhead box O1 (FOXO1) locus on chromosome 13 , resulting in the mis-expression of a chimeric PAX3-FOXO1 or PAX7-FOXO1 oncoprotein (FIG. 1) . Recently, several novel PAX3 gene fusion partners have also been identified [14] [15] [16] [17] (FIG. 1) , although the clinical significance of these variant PAX3 fusions is presently unknown. Of note, ~20% of ARMS lack cytogenetic or molecular evidence of these translocations and are now classified as fusionnegative ARMS 18 . Importantly, fusion-negative ARMS is less aggressive than fusion-positive ARMS and behaves similarly to ERMS with regard to clinical outcome 19 .
As the ultrastructural features of RMS cells resemble primitive skeletal muscle-lineage precursors, RMS has often been examined through the prism of 'myogenesis gone awry' . Thus, the wealth of knowledge that has been obtained over the past decades regarding the normal mechanisms underlying myogenesis has been invaluable in garnering insights into RMS. Despite these advances, therapies targeting molecular RMS oncogenic drivers are lacking. (For excellent reviews in these areas, we refer readers to Sokolowski et al. 20 , Hettmer et al. 21 ; and Keller and Guttridge 22 .) Consequently, investigators have made substantial efforts over the past decade to generate new genetic tools with which to dissect RMS (FIG. 2) , each with important advantages (FIG. 3) . Now is a promising time for the discovery of genes involved in RMS patho genesis and therein the identification of new clinical targets, which we additionally discuss below.
Genomics of ERMS and ARMS human tumours
Clinical and histopathological criteria determine a patient's individual risk and appropriate risk-stratified RMS therapy
. However, predicting individual treatment response remains imprecise, especially for patients who have intermediate-risk RMS. With the hypothesis that tumour biological signatures might offer improved risk stratification, several groups have utilized gene expression profiling, array comparative genomic hybridization (aCGH) and targeted sequencing to interrogate RMS 19, 23, 24 . These studies have clearly revealed that fusion-negative ARMS is molecularly and clinically indistinguishable from ERMS, and that known oncogenic driver mutations are notably more common in ERMS than in ARMS.
More recently, two groups performed whole-genome sequencing of RMS tumours 17, 25 . Similar to previous studies 19 , both groups found that ERMS demonstrated a higher background mutation rate, as well as a higher number of single nucleotide variants and copy number variants (CNVs), compared to ARMS. Both groups also reported a paucity of mutations in genes known to be recurrently mutated across many cancer types in fusionpositive ARMS. In ERMS, by contrast, both groups confirmed previously identified recurrent mutations in NRAS, KRAS, HRAS, neurofibromin 1 (NF1), fibroblast growth factor receptor 4 (FGFR4), PI3K catalytic subunit-α (PIK3CA), TP53 and β-catenin (CTNNB1), as well as novel mutations in F-box and WD repeat domain-containing 7 (FBXW7), which encodes an E3 ubiquitin ligase, and BCL-6 co-repressor (BCOR), which encodes a transcriptional repressor that interacts with histone deacetylases (HDACs) 17 . High-throughput screening of primary cells from patient-derived xenografts dispersed in single-cell suspension culture further showed that HDAC inhibitors and agents that increase oxidative stress displayed the greatest cytotoxicity. Although activating mutations in the RAS family associate with intermediate and high-risk ERMS, targeting the RAS pathway or PI3K (which can be activated by RAS), either alone or in combination, demonstrated no detectable anti-ERMS cytotoxicity 25 . Overall, these efforts highlight the genomic heterogeneity of ERMS and the lack of a single genetic vulnerability that might be targeted.
Genetically modified RMS cells
Cell-based systems remain important RMS tools, given the ease and speed of genetic manipulation. A battery of human RMS cell lines are available for probing -a collection that has been expertly reviewed 20, 26 . Here, we focus instead on genetically modified RMS model cells.
Genetic modelling of ERMS in human muscle progenitor cells. To delineate the genetic changes underlying RMS initiation and progression, Linardic et al. 27 interrogated the alterations needed to convert normal skeletal muscle precursors to a neoplastic state. Both human fetal skeletal muscle cell (SkMC) precursors and postnatal human skeletal muscle myoblast (HSMM) cells were transformed by stably expressing SV40 large-T and small-t antigen oncoproteins (T/t-Ag), human telomerase catalytic subunit (hTERT) and oncogenic HRAS-G12V (REF. 27 ). Although the combination of T/t-Ag and hTERT expression in SkMCs resulted in long-term proliferative capacity in culture, the addition of HRAS-G12V was needed for tumorigenesis in mouse xenograft models. Interestingly, HSMM-derived xenografts resembled ERMS upon immunohistochemical profiling, whereas SkMC-derived xenografts failed to exhibit classic ERMS or ARMS histology by light microscopy, arguing that the cell of origin influences tumour morphology. These experiments highlighted potential combinations of genetic perturbations and permissible cell types sufficient to yield ERMS, and they also indicate that multiple genetic alterations are necessary for ERMS tumorigenesis.
RAS pathway and modified cells. Expression of oncogenic HRAS or NRAS blocks myogenic differentiation in mouse muscle cells, and thus phenocopies the perceived developmental arrested state of RMS 28 . As mentioned above, RAS mutations are predominantly found in ERMS [29] [30] [31] [32] , with NRAS mutations being most frequent
Box 1 | Risk stratification of RMS
The treatment of rhabdomyosarcoma (RMS) is based upon a risk stratification that includes pretreatment staging, post-surgical clinical grouping and tumour histology (embryonal RMS (ERMS) or alveolar RMS (ARMS)). Staging defines the tumour size, invasiveness, lymph node involvement, tumour location and presence of metastasis (collectively referred to as the 'TNM classification system' for cancer staging). Post-surgical clinical grouping defines the extent of residual tumour following surgery, regional lymph node involvement, and presence of metastasis. All non-metastatic ERMS at favourable sites and totally resected ERMS at unfavourable sites are 'low risk'. at 11.7%, followed by KRAS (6.4%) and HRAS (4.3%) mutations 17 . In total, the RAS pathway was mutationally activated in 45% of all ERMS 17 , and more specifically in 58% of the intermediate and high-risk ERMS 25 . Studies have also shown that germline HRAS mutations on chromosome 11p15.5 in Costello syndrome predispose individuals to ERMS and other embryonic tumours [33] [34] [35] . Hettmer et al. 36 further illuminated the role activated RAS can have as an RMS driver. Here, oncogenic KRAS-G12V was ectopically expressed in freshly sorted murine satellite cells lacking cyclin-dependent kinase inhibitor 2A (Cdkn2a), which encodes INK4A and ARF; these cells were then transplanted into immunocompromised mice. Recipients developed pleomorphic RMS, whereas mice that were injected with similarly modified non-myogenic progenitor cells exhibited pleomorphic sarcomas lacking myogenic differentiation (also known as undifferentiated pleomorphic sarcoma (UPS)). Transcriptional profiling of these RMS tumours recapitulated gene signatures of human ERMS and ARMS. Furthermore, as a proof in principle, treatment of two cell lines derived from these mouse tumours with the RAS signalling antagonist U0126 inhibited proliferation. Interestingly, these data contradict findings mentioned above from cells that were dispersed from patient-derived ERMS xenografts, which included samples harbouring activating NRAS mutations. These discrepancies highlight the utility of complementary approaches from diverse systems and the further need for deeper interrogation of RMS signalling.
Genetic changes that drive ARMS in human myoblasts. Although PAX-FOXO1 cellular phenotypes are known to be context dependent, PAX3-FOXO1 activity in cultured cells had largely been limited to undifferentiated fibroblasts or murine myoblasts. Thus, Linardic et al. 37 probed PAX3-FOXO1 pathogenesis in both SkMCs and HSMM cells, which showed that PAX3-FOXO1 bypasses cellular senescence through methylation of the CDKN2A promoter. A similar trend towards downregulation of INK4A was found in human ARMS tissue microarrays and cell lines. These findings pointed towards the loss of INK4A activity as an early step in ARMS.
Naini et al. 38 next tested for additional genetic changes that are necessary to drive tumorigenesis. As a subset of ARMS demonstrate upregulation of MYCN and stabilization of telomeres 27, 39 , MYCN and hTERT were subsequently expressed in PAX3-FOXO1 HSMM cells. These alterations resulted in transformed cells that exhibited tumorigenesis in xenograft models, but with a surprising caveat: the order of genetic changes was critical. Tumours only resulted when PAX3-FOXO1 cells were first transformed with hTERT followed by MYCN, whereas cells transformed with MYCN then hTERT were not tumorigenic. These studies not only reveal the genetic lesions that can drive RMS in vivo but also provide the provocative notion that the sequence of alterations is biologically critical.
PAX3-FOXO1 mice and ARMS
The PAX3-FOXO1 and PAX7-FOXO1 oncogenic transcription factors generated by the aforementioned recurrent chromosomal translocations are strikingly similar [11] [12] [13] , fusing PAX3 or PAX7 DNAbinding domains to the FOXO1 transcriptional activation domain. As PAX3-FOXO1 tumours are more 18, 40, 41 , PAX3-FOXO1 has been the focus when designing ARMS models. Four initial studies reported PAX3-FOXO1 mouse models, each with unique transgenic or Cre-lox conditional approaches [42] [43] [44] [45] . Although exhibiting informative developmental phenotypes, these genetically engineered mouse lines lacked evidence of tumorigenesis, arguing that targeting the right cellular compartment of origin and/or profiling PAX3-FOXO1 in tumourpromoting genetic backgrounds was likely to be critical for designing a tumorigenic PAX3-FOXO1 model. Indeed, both considerations were proven to be influential.
A tumorigenic ARMS model. The ARMS model 46 utilizes an elegant conditional knock-in allele, with human FOXO1 conditionally inserted into an intron of the mouse Pax3 gene, so that in the absence of Cre-mediated recombination, wild-type Pax3 expression is unaltered. Upon Cre exposure, however, the endogenous Pax3 locus is then converted to a Pax3-FOXO1 allele, fusing the first seven exons of mouse Pax3 to an embedded 9.3 kb genomic fragment containing human FOXO1 exons 2 and 3.
Activation of Pax3-FOXO1 expression from one allele, in the absence of any tumour-promoting background mutations, at a late stage in embryogenesis and within postnatal terminally differentiating myogenic factor 6 (Myf6; also known as Mrf4)-positive muscle tissue, induced tumorigenesis, although as a rare event and with a latency of over 1 year. With homozygous Pax3-FOXO1 expression in a Cdkn2a-or Trp53-null background, however, tumorigenesis was markedly accelerated and penetrance increased to 100% 47 . Tumours from these mice resembled human ARMS both morphologically and when examined using gene set enrichment analysis 47 . This model has been effectively exploited to investigate important issues regarding ARMS pathobiology (summarized here, but described in more detail in the sections below). These issues include: mechanisms of ARMS evasion from insulin-like growth factor 1 receptor (IGF1R) inhibitor resistance 48 ; the influence of interleukin-4 receptor (IL-4R) signalling on ARMS tumour progression 49 ; PAX3-FOXO1 cell-cycle-dependent regulation and expression 50 ; and whether the tumour response to pharmacological inhibition is dependent on the cell of origin 51 .
Insights from ERMS animal models
In comparison with ARMS, ERMS is genetically heterogeneous 17, 19, 25 . Although most cases of ERMS arise as sporadic tumours, ERMS is also known to associate with a number of familial syndromes driven by germline mutations in oncogenesis-related signal transduction pathways [52] [53] [54] [55] . Consistent with this notion, ERMS tumorigenesis in mouse models has been more varied, arguing that multiple pathways are capable of driving ERMS. p53 pathway and ERMS. Humans with germline mutations in TP53 are at increased risk of developing ERMS 55, 56 , although TP53 mutations are identified at rather low frequencies (5-6%) in sporadic RMS 55, 57 . Consistent with these observations, mice that are functionally null for p53 exhibit ERMS tumorigenesis, but at comparatively low levels (~5%) 58 . These findings suggest that additional genetic aberrations help to drive ERMS, such as increased expression of the p53 physical inhibitor MDM2 (REFS 59, 60) . Thus, mutant Trp53 mice have been utilized as a sensitized background to screen for other potential drivers of ERMS. For example, compound mutant mice null for both Trp53 and FBJ osteosarcoma oncogene (Fos) demonstrate a high penetrance of ERMS (93% by 6 months of age), which is restricted to the face and orbit 61 , Mouse models utilize the Cre-lox system, and Cre drivers are controlled by promoters from transcription factors that regulate myogenesis. Drosophila melanogaster models use the GAL4-UAS system to direct the expression of PAX7-FOXO1 in skeletal muscle. Zebrafish models express KRAS G12D directly from tissue-specific promoters. The diversity of these models and the heterogeneity of the resulting histologies suggest that there are many potential permissive states during muscle development for RMS genesis. The genetic makeup of each model is shown along with its corresponding myogenic cellular source. Also illustrated is the mouse model arising from the non-muscle adipose protein 2 (aP2) lineage. Coloured circles adjacent to the genotypes indicate the different forms of tumours that arise in their corresponding models. ARMS, alveolar RMS; cdh15, cadherin 15; Cdkn2a, cyclin-dependent kinase inhibitor 2A; ERMS, embryonal RMS; FOXO1, forkhead box O1; LSL, lox-STOP-lox; Mhc, myosin heavy chain; Myf, myogenic factor; mylz2, myosin light chain 2; MyoD, myogenic differentiation 1; NOS, not otherwise specified; PAX, paired box; Ptch1, Patched 1; rag2, recombination activating gene 2; Smo, Smoothened.
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Xenograft and orthotopic models 62 . These findings indicate that specific combinations of genetic events drive RMS in particular locations, a connection that is likely to become more apparent with further comprehensive analysis of clinically categorized tumours.
Hedgehog signalling and ERMS. Whereas sonic hedgehog (SHH) signalling is active during the early development of muscles and is largely quiescent postnatally 63 , several lines of evidence illustrate a role for the SHH pathway in ERMS. First, a germline mutation in the SHH inhibitor Patched 1 (PTCH1) locus (which causes nevoid basal cell carcinoma syndrome; also known as Gorlin syndrome) causes low levels of ERMS in humans 54, 64, 65 . Additionally, 33% of ERMS have loss of chromosome 9q22, which contains the PTCH1 gene 66 , 53% have gain of chromosome 12q13.3, which contains the SHH downstream transcription factor GLI1 (REF. 32 ), and 73% display increased GLI1 protein when examined by immunohistochemistry 67 . As no activating mutations have been identified in the SHH pathway in ERMS, the mechanisms accounting for SHH activation in ERMS remain elusive. Furthermore, studies have yielded differing observations regarding the clinical significance of a SHH pathway signature in ERMS 68, 69 . Nonetheless, components of the SHH pathway (Ptch1, Suppressor of fused (Sufu) and Smoothened (Smo)) have been effectively exploited for ERMS modelling.
Mice with heterozygous deletion of Ptch1 develop ERMS similar to the human tumour, but with low penetrance (4-15%) 65, 70, 71 . PTCH1 mutations have also been reported to associate with mutations in SUFU 72 , a GLI1 antagonist. Of note, heterozygous loss of Sufu itself, however, is not tumorigenic, and instead requires concomitant mutation of Trp53 to induce ERMS, again with low penetrance (9% of mice) 73 . A more robust SHH pathway-based ERMS mouse model utilized a constitutively activated form of the SHH SMO receptor (Smo M2 ) embedded into the Rosa26 locus 74 . Global activation of the embedded Smo M2 allele phenocopies human Gorlin syndrome, as these mice develop basal cell carcinoma, medulloblastoma, and ERMS (with 100% penetrance). Expression profiling of these tumours revealed overlapping gene signatures, including platelet-derived growth factor (PDGF) and components of the IGF signalling pathway, suggesting a common link between these seemingly unrelated malignancies. Interestingly, Hettmer et al. 75 point out that, upon further histopathological review,
Rosa26-Smo
M2 ;CAGGS-CreER tamoxifen-induced tumours microscopically show prominent cytodifferentiation and lack nuclear atypia (CAGGS is a synthetic hybrid element, containing the cytomegalovirus (CMV) early enhancer and chicken β-actin promoter, that drives global, constitutive cDNA expression) 76 ; therefore, these tumours more closely resemble the benign skeletal muscle lineage tumour, fetal rhabdomyoma (FRH) 75 . Based on this observation, molecular analysis of a cohort of human FRH revealed that the majority carried functionally relevant aberrations of PTCH1. In tandem, these studies argue for misregulated SHH signalling as a driver of human myogenesis-related neoplasia.
HGF as an ERMS driver. Expression of the MET receptor tyrosine kinase is influenced by PAX3 during murine limb development 77 , and aberrant MET signalling owing to constitutive activation via overexpression of the MET ligand hepatocyte growth factor (HGF) has been associated with RMS 78 . Thus, Sharp et al. This model has also uncovered various factors that promote ERMS metastasis, including the actin filamentplasma membrane linking protein ezrin and the sine oculis homeobox homologue 1 (SIX1) transcription factor [82] [83] [84] . Intriguingly, ezrin expression is epigenetically regulated and can be increased by HDAC inhibitors and DNA demethylating agents, which therein facilitates aggressive metastasis in vivo 85 . These findings suggest the need to exercise caution regarding epigenetic modulators in RMS, especially as HDAC inhibitors and DNA demethylating agents have been considered for RMS therapy 86 . Muscular dystrophies and ERMS. Muscular dystrophies (MDs) are a heterogeneous group of genetic disorders driven by inherited mutations in genes that encode proteins that are critical for the association of the muscle fibre with the extracellular matrix. Mutation of the DMD gene, which encodes dystrophin, a key protein in the dystrophin-associated glycoprotein (DAG) complexes, causes X-linked Duchenne MD, whereas mutations in other components of DAG complexes account for additional MD variants. Notably, rare cases of ARMS and ERMS have been reported in patients with Duchenne MD 87, 88 . Consistent with these observations, mutation of DAG complex members in mice also results in RMS (reviewed in REF. 89 ). For example, Dmd 90,91 and dysferlin (Dysf) [92] [93] [94] mutations in mice result in RMS, although at higher rates than those seen in humans; this is likely to be due to the fact that the milder dystrophic phenotypes that occur in mice allow for a comparatively longer window for tumorigenesis. Recently, somatic deletions in DMD have been identified in sporadic human myogenic tumours, including ERMS 95 .
The mechanism underlying RMS in MD is postulated to involve increased oxidative stress, which promotes genomic instability. Further interrogation of the causal connection between MDs and RMS is therefore likely to provide further insight into RMS pathobiology.
Insights from zebrafish ERMS models. Zebrafish are excellent neoplasia models, possessing similar mechanisms of tumorigenesis to humans 96 , and the amenability of these animals to real-time organism-level examination is technically powerful. Regarding RMS, zebrafish also possess striated muscle that is genetically and morphologically equivalent to that in humans 97 . Thus, Langenau and colleagues 98 generated transgenic lines expressing oncogenic human KRAS (KRAS G12D ) via the rag2 (recombination activating gene 2) promoter, which possesses a MyoD-binding E-box motif and drives expression in satellite cells and differentiating myoblasts. Tumours were seen in ~50% of all rag2-KRAS G12D fish by 80 days post-fertilization, and they exhibited ERMS-type histology. Genes that were upregulated in zebrafish ERMS (zERMS) overlapped with mouse and human ERMS. Similar to mouse models, tumour burden was increased by loss of tp53.
Using whole-animal imaging and differential labelling with transgenic fluorescent protein reporters, subpopulations of better-differentiated (myogeninpositive (myog + )) and less-differentiated (myf5 + ) myoblast-type cells were identified in zERMS tumours. Interestingly, the myog + cells were found to be the first to metastasize. By contrast, myf5 + cells were comparatively more proliferative and only populated new metas tatic tumours after initial seeding by myog + cells 99 . These findings nicely showed that distinct molecular signatures and heterogeneous cell populations preferentially account for tumour-forming behaviour versus metastasis potential.
As a concluding thought, although an ARMS fish model has yet to be reported, given that PAX3 and PAX7 are conserved in zebrafish we speculate that a bona fide ARMS fish model is likely to be reported in the near future and -similar to the ERMS model -it will benefit from the powerful advantages of the zebrafish platform.
Mouse models of pleomorphic RMS Conditional expression of Kras
G12V via a Cyp1A1-promoter driven Cre (Ah-Cre) (which drives transgenic expression in multiple organs and tissues, including skeletal muscle) was profiled in Trp53 +/− , Trp53 −/− , and dominant-negative Trp53 R172H/+ backgrounds 100 , and showed pleomorphic RMS tumorigenesis at rates of 6%, 94%, and 100%, respectively 100 . In a complementary study, pleomorphic RMS was shown to arise with 100% penetrance after in vivo electroporation of Cre-encoding cDNA in Trp53 null mice with a Kras G12D conditional allele. It is interesting to note, however, that pleomorphic RMS has not been reported in the zebrafish model that similarly profiled KRAS G12D in a tp53-mutant background. Whether this reflects an inability of zebrafish to develop pleomorphic RMS, or differing expression levels and/or profiles, remains unclear; further investigation into this issue will probably yield greater insight into fundamental aspects of the pathobiology of pleomorphic RMS.
Drosophila as an RMS model system Drosophila melanogaster model systems, although they do not precisely recapitulate all facets of mammalian tumorigenesis, provide distinct technical advantages not available to mammalian model platforms 101 . Similar to zebrafish, real-time, whole-animal imaging is a powerful advantage of Drosophila systems. Additionally, Drosophila models are exceptional for performing unbiased forward genetic screens, probing for genetic enhancers and suppressors of phenotypes of interest in a remarkably comprehensive, rapid fashion.
The core myogenesis mechanism is conserved between Drosophila and mammals. Similarly, the PAX3 and PAX7 orthologues of Drosophila (Gooseberry and Gooseberry-neuro) show remarkable conservation with their human counterparts 102, 103 . Using the bipartite UAS-GAL4 conditional expression system 104 and myosin heavy chain driver (Mhc; which is active in differentiating myoblasts), conditional expression of human PAX3-FOXO1 or PAX7-FOXO1 causes animal lethality 105 . The authors subsequently focused on PAX7-FOXO1, which demonstrates stronger phenotypes in flies owing to better sequence identity between human PAX7 and the fly orthologues. Although no tumours were seen, PAX7-FOXO1-expressing cells, which were monitored by the co-expression of GFP, were subsequently found to be aggressive and infiltrate non-native tissue compartments. As a proof of concept for the utility of this model for genetic screening, the authors showed that heterozygous loss-of-function mutations in ras suppressed PAX7-FOXO1 lethality, whereas an activating ras G12V mutation accelerated the onset of lethality. Exploiting this model, the rolling pebbles (rols) gene was isolated as a dominant PAX7-FOXO1 suppressor 106 . The rols gene encodes an adaptor molecule that is necessary for coordinating the intracellular machinery that drives myoblast cell-cell fusion in syncytial muscle [107] [108] [109] 
. Tanc1 (tetratrico peptide repeat, ankyrin repeat and coiled-coil containing 1; the mouse rols orthologue), which was previously uncharacterized in mammalian muscle, was next shown to be essential for myoblast fusion in mouse myoblasts, and to be a PAX3-FOXO1 target that is mis-expressed in mammalian PAX3-FOXO1 cells (both stably infected PAX3-FOXO1 mouse C2C12 myoblasts and human ARMS cells). Notably, restoring TANC1 expression back to wild-type levels by RNA interference in ARMS cells restored terminal differentiation and myoblast fusion potential. As the genetics of myoblast fusion are poorly understood in mammals, the notion that dysregulated myoblast fusion potential might underlie RMS had not been previously explored. Importantly, these studies revealed for the first time that myoblast fusion pathobiology impinges upon RMS pathogenesis. The Rols/TANC1 studies also affirmed that insights uncovered from the PAX7-FOXO1 fly model influence our understanding of human ARMS.
Hippo signalling in RMS model systems
Two recent studies -one on ARMS and the other on ERMS -have pointed towards a role for Hipporelated signalling in RMS pathogenesis. Probing the PAX3-FOXO1 HSMM platform described above, Crose et al. 110 uncovered the RAS-associated domain family member 4 (RASSF4) as an effector of PAX3-FOXO1-mediated senescence suppression. In this same report, the Drosophila PAX7-FOXO1 model was utilized to show that a loss-of-function mutation in the fly orthologue of RASSF4 suppresses PAX7-FOXO1-induced lethality. The authors next showed that RASSF4 is overexpressed in ARMS cell lines and human tumours, promotes cell cycle progression, and facilitates RMS xenograft tumorigenesis. Using cell-based studies, RASSF4 was shown to promote ARMS through suppression of the Hippo pathway tumour suppressor mammalian STE20-like protein kinase 1 (MST1; also known as STK4). In parallel, Yesassociated protein 1 (YAP1) was shown to be upregulated in ARMS. However, as there was no direct link between RASSF4 and YAP1 signalling, non-canonical pathways are likely to be involved.
In a parallel study, Tremblay et al. 111 interrogated 78 ARMS and 196 ERMS tumour samples for YAP1 expression, which revealed that YAP1 expression is more intense and preferentially nuclear in ERMS. Induced expression of a constitutively active form of YAP1
S127A
Box 2 | Myoblast cell recognition and fusion
Skeletal muscle is one of a rare number of syncytial somatic tissues. Thus, the patterning of skeletal muscle requires that precursor myoblasts fuse into multinucleated myotubes. This complicated process involves migration and cell recognition, followed by primary and secondary myotube formation. Much of our understanding is from Drosophila melanogaster and mouse myoblast C2C12 cell studies 149 . In Drosophila, mesodermal precursors in the embryo give rise to founder cells and fusion-competent myoblasts (FCMs). The founder cells drive the onset of myoblast fusion by attracting FCMs. Fusion is dependent on immunoglobulin superfamily (IgSF) transmembrane proteins, including Dumbfounded (Duf; also known as Kirre) and Rst/IrreC (roughest/irregular optica chiasma C), and their interaction with Sns (sticks and stones) 150 . The founder cells exclusively express Kirre, which demonstrates functional redundancy with Rst 151, 152 . Following the Sns-Kirre/Rst interaction, the cytoplasmic domain of Kirre/Rst recruits Rols (rolling pebbles) 107, 109 and Schizo/Loner proteins 153 . Similarly, Kirrel is required for myoblast fusion in zebrafish 97 . These events lead to Rac1 recruitment via the Arf6 GTPase, which, along with Mbc (Elmo), initiates the Scar (Wave) pathway 154 . These interactions culminate in the rearrangement of cytoskeletal elements and myotube formation.
In mammalian myoblasts, cadherins, integrins, and disintegrin and metalloproteinases (ADAMs) localize to the cell-cell contact interface during fusion events. Additionally, intracellular signalling proteins, such as β-catenin, creatine kinase, kindlin 2 and others, localize to the site of cell contact and regulate cytoskeletal rearrangement 154 . Studies in C2C12 cells have established that TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing protein 1; the mammalian Rols orthologue) is required for myoblast fusion 106 . Nephrin (the mammalian Sns orthologue) is required for the secondary fusion of myoblasts to form nascent myotubes 155 . However, whether Nephrin interacts with Kirrel in mammalian myoblasts is not clear. Recently, the protein Myomaker (also known as TMEM8C) has been shown to be essential for myoblast fusion in mice and, interestingly, is unique to muscle cells 156, 157 . in Myf5 + or MyoD + cells drove ERMS in mice, whereas YAP1 S127A expressed in Pax7 + quiescent satellite cells was not tumorigenic. However, upon myofibre injury, which activates satellite cells, ERMS tumorigenesis was observed. Interestingly, cessation of YAP1 signalling resulted in marked reduction in tumour size owing to recovered differentiation potential of the neoplastic rhabdomyoblasts. These findings demonstrate that YAP1 promotes tumorigenesis in activated satellite cells by inducing proliferation and imposing a differentiation blockage.
Of note, previous studies have similarly interrogated YAP activity in hepatocellular carcinoma 112, 113 , and have reported antitumorigenic responses in mouse xenograft studies with newly engineered dominantnegative (interfering) YAP-like peptides 113 .
Whether these agents will demonstrate efficacy against RMS is an intriguing question.
Interrogating the cellular origins of RMS Although RMS histologically demonstrates muscle precursor cell-like features, it is curious that RMS can arise in tissues that lack skeletal muscle [114] [115] [116] [117] [118] . Thus, elucidating which cell or cells give rise to RMS remains a perplexing and fascinating question -a question that recent animal models have elegantly probed.
Zebrafish myoblast differentiation and RMS.
Differential labelling of zERMS tumour cells was utilized to probe for the cell type that gives rise to zERMS 98 . rag2-dsRED2 (red fluorescent protein) and rag2-KRAS G12D constructs were co-injected into α-actin-GFP transgenic single-cell embryos (α-actin drives expression in mature muscle cells and not satellite cells), from which four cell populations were generated and present in zERMS: dsRED2 + , dsRED2 + GFP + , GFP + and dsRED2 − GFP − , with all four populations confirmed positive for rag2-KRAS G12D . Each population was serially transplanted into irradiated fish recipients, which identified the dsRED + population as tumorigenic. Reverse transcription PCR (RT-PCR) analysis revealed that this population exhibited an expression signature similar to activated satellite cells (MET + , m-cadherin + (also known as cadherin 15), myf5 + , myoD − , and low levels of pax7). Thus, the authors concluded that the zERMS progenitor is an activated satellite cell. In a complementary study, KRAS G12D was conditionally expressed in cells at different stages of myogenic differentiation to identify zebrafish cell types that are permissive for zERMS 119 . KRAS G12D expression was regulated by either the rag2 or cdh15 (which encodes m-cadherin) promoters, which are active in early muscle progenitors, or by myosin light chain 2 (mylz2; also known as mylpfa), which is expressed in differentiating myoblasts. Consistent with these expression profiles, rag2 and cdh15 RMS comprised myoblast-like cells that were histologically reminiscent of spindle cell RMS, whereas mylz2 tumours more closely resembled maturing skeletal muscle. As RMS differentiation status has been correlated with aggressiveness and poorer outcomes 99, 120 , these studies notably suggest that the tumour cell of origin underlies tumour clinical behaviour.
Cell of origin influences RMS and UPS tumorigenesis.
To explore cell susceptibility to ERMS tumorigenesis, Rubin et al. 121 utilized multiple myogenic Cre drivers to selectively delete Trp53 -either with or without heterozygous Ptch1 deletion -through various developmental time points in myogenesis. Cre drivers used included: M-Cre (transgenic Cre with a Pax3 hypaxial somite enhancer and minimal Pax3 promoter), which was active in the prenatal and postnatal hypaxial lineage as well in the postnatal satellite cells 122 ; Myf5-Cre, which was active in myoblasts, quiescent and activated satellite cells, and brown adipose precursors; Myf6-Cre, which was active in maturing myoblasts and myotubes (although recent reports note its activity in satellite cell precursors) 122 ; and Pax7-CreER, which was active in quiescent and activated satellite cells.
Discrete homozygous Trp53 deletion using any of these Cre drivers demonstrated tumorigenesis (with a range of 13-56%), with heterozygous Ptch1 deletion increasing tumour frequency. Intriguingly, a spectrum of tumours was derived from all four Cre drivers, including ERMS, ARMS, pleomorphic RMS, and UPS. Notably, gene expression profiling revealed a decreasing gradient of myogenic marker genes in ERMS, spindle cell RMS, and UPS; this supports the idea that, although originating from the same cellular compartment, these tumours lie in a previous unrecognized myodifferentiation continuum.
In a complementary study, Blum et al. 123 conditionally expressed oncogenic Kras G12D in a Trp53-null background to further explore the myogenic cell (or cells) of origin for the RMS subtypes and UPS, focusing on Pax7 + MyoD − (quiescent) and Pax7 + MyoD + (activated) satellite cells. Utilizing a Pax7-CreER driver, a spectrum of tumours was observed when Kras G12D expression was induced via tamoxifen injection in mice over 6 weeks old. Tumorigenesis was 100% penetrant and mutifocal (with a median tumour-free survival of 44 days), with 62% of tumours demonstrating UPS histology, and the remainder consistent with RMS. To profile Kras G12D activity in postnatal activated satellite cells, the authors generated a new MyoD-restricted CreER driver (MyoD CE ) and induced expression in mice as before. In comparison with Pax7-CreER, latency was significantly longer (with a median tumour-free survival of 153 days) and tumorigenesis was unifocal. The authors postulate that this decreased efficiency stems from a comparatively small number of MyoD cells that are present under homeostatic conditions. Strikingly, all tumours examined were UPS, with microarray analysis suggesting that these UPS malignancies clustered with Pax7-CreER-derived UPS. In total, these findings and those above argue that RMS and UPS have both overlapping and distinct cells of origin within the myogenic lineage.
A recent mouse model illuminates the potential for ERMS to arise in tissues devoid of skeletal muscle 124 . In this study, conditional expression of constitutively active Smo M2 using the adipose protein 2 (aP2)-Cre driver 125 unexpectedly resulted in 80% of aP2-Cre;Smo M2 mice developing ERMS head and neck tumours. Gene expression profiling revealed an embryonic muscle gene signature similar to previously characterized mouse and human ERMS tumours. aP2-Cre, previously reported to be adipose restricted, was recently shown to be more broadly expressed in tissues such as the capillary endothelium of the heart and intermyofibrillary cells in skeletal muscle 126 . Although the possibility exists that aP2-Cre in these studies was expressed in a rare population of myogenic cells, lineage tracing supported a lack of skeletal muscle expression. 127 . Thus, the gene signature of ERMS, at least in this setting, reflects the final state of the tumour rather than the presumptive cell of origin.
Abraham et al. 51 used a battery of Cre drivers to activate Pax3-FOXO1 and delete Trp53 at different stages of pre-and postnatal muscle development, which showed that the cell of origin underlies RMS histology. Activation of Pax3-FOXO1 and deletion of Trp53 in the fetal muscle lineage (M-Cre), embryonic and fetal muscle lineage (Myf6-Cre), or in postnatal satellite cells (Pax7-CreER) resulted in tumorigenesis. However, only tumours from M-Cre and Myf6-Cre resulted in ARMS histology, whereas the Pax7-CreER tumours resulted in pleomorphic RMS. This study also revealed that transcriptional expression of Pax3-FOXO1 is epigenetically regulated and differed substantially based on the targeted cell type, therein leading to the identification of the HDAC inhibitor entinostat as a pharmacological agent that can convert in vivo Pax3-FOXO1-positive ARMS to a fusion-negative RMS state through direct transcriptional suppression of the Pax3-FOXO1 allele. As fusion-negative ARMS demonstrates a much more favourable prognosis in comparison with fusionpositive tumours, these studies propose a tantalizing new therapeutic approach for the clinical treatment of ARMS.
Present and future RMS therapy Improvements in identifying new therapeutic agents and approaches to treat RMS have been lacking. Incomplete understanding of the derailed molecular machinery and the cellular source of RMS are primary reasons for the slow advancements. However, the latest generation of powerful and diverse genetic model systems are importantly suggesting new potential avenues for precision therapy in RMS (FIG. 4) .
The Pax3-FOXO1 mouse model has provided valuable insights into the identification of new potentially targetable pathways 47 . IGF signalling has long been associated with ARMS pathogenesis and the development of resistance to therapy 21, [128] [129] [130] [131] . Using this model, it was shown that nuclear localization of IGF1R correlated with tumour establishment in vivo 132 and that activation of ERBB2 with IGF1R contributes to drug resistance 48 . Therefore, a combinatorial approach that can block both ERBB2 and IGF1R might be desirable. IL-4 signalling, which is necessary for the migration and fusion of myoblasts into myotubes 133 , promotes tumour progression in ARMS, and blocking IL-4 signalling with an IL-4R-specific antibody in this model results in decreased metastasis and increased survival 49 .
Using this ARMS mouse model and cell lines, it is now known that Pax3-FOXO1 expression is dynamic and is most abundant in the G2 phase of the cell cycle 50 . Upon upregulation, Pax3-FOXO1 then initiates a transcriptional programme that facilitates checkpoint adaptation under stress conditions. Interestingly, targets of Pax3-FOXO1 sensitize tumours to mitotic inhibitors, which block proteins such as Polo-like kinase 1 (PLK1) and Aurora kinase B (AURKB), which might be therapeutically exploitable. Indeed, inhibition of PLK1 increases ubiquitylation and degradation of PAX3-FOXO1 and, more importantly, promotes tumour regression in a xenograft ARMS model 134 . The KRAS G12D -induced zERMS model has similarly been utilized to screen for new anti-RMS compounds. Several families of drugs, including histone methyltransferase inhibitors 135 , translation initiation inhibitors 136 and, interestingly, glycogen synthase kinase 3 (GSK3) inhibiting 6-bromoindirubin-3ʹ-oxime (BIO) 137 , have so far been identified. GSK3 inhibition has further been shown to trigger WNT-β-catenin pathway signalling, which results in diminished self-renewal of ERMS cells in vivo. Whereas GSK3 inhibitors have been tested clinically in different diseases [138] [139] [140] , their effectiveness in ERMS remains to be elucidated. Using a heat-shock inducible HRAS G12V (hsp70-HRAS G12V ) zebrafish model, inhibition of MEK1 and ribosomal protein S6 kinase 1 (S6K1) has been shown to suppress tumour growth 136 . Additionally, PI3K activation has been observed to be present in 82.5% of RMS, with the RAS-ERK pathway coactivated in 36% and 46% of ARMS and ERMS, respectively 141 , and reciprocal crosstalk signalling is observed between these two signalling pathways in multiple RMS cell lines. Treatment of the ERMS RD cell line with AZD8055 (an mTOR inhibitor) and AZD6244 (a MEK1/2 inhibitor) enhanced inhibition of xenograft tumour growth. These findings argue for dual-agent therapy in PI3K-and RAS-ERK-activated RMS. Similar combinatorial lethality in RMS results from dual inhibition of Hedgehog and PI3K-mTOR signalling using the GLI1 and GLI2 inhibitor GANT61 and the PI3K and mTOR inhibitor PI-103 in vitro and in vivo by caspase-dependent apoptosis 142 .
Concluding remarks
We have witnessed remarkable advances in the battery of model systems that are now available to dissect RMS pathobiology, and new provocative models Nature Reviews | Cancer continue to be developed 143 . These models also indicate viable approaches for the genetic and molecular dissection of other clinically problematic non-RMS sarcomas. As further insights are garnered, the field no doubt will focus increasingly on the molecular signatures of one's individual tumour through the power of patient-derived tumour xenografts -an approach that is coming to fruition [144] [145] [146] [147] . An ongoing challenge facing the RMS community -and a challenge faced by the paediatric cancer community in general -is the relative paucity of patients, which complicates the design and statistical power of new clinical trials. Thus, new trials often require the efforts of cooperative consortiums. Again, in this area, new initiatives continue to be developed, which will increase our overall understanding of RMS genomics. These efforts in tandem will allow for refined risk-stratification, which in turn will inspire therapy tailored towards each patient's specific tumour -that is, 'precision therapy' 148 -thereby fulfilling a long-standing goal of oncologists to gravitate away from generalized, systemic cytotoxic therapeutics. Achieving this will require multidisciplinary translational research groups to further interrogate preclinical models and promote new treatment regimens. Such improvements will not only serve to improve RMS morbidity and mortality in general but also spare growing numbers of children from treatment-related side effects that otherwise complicate their wellbeing for the remaining decades of their life. biology and offer potential for targeted therapeutic intervention. The diversity of targets and multitude of agents illustrates the need to leverage model systems to focus clinical trial efforts in the small RMS patient population. The drugs that target different signalling pathways are listed in boxes adjacent to the corresponding proteins, whereas other targets are listed in an independent box. ALK, anaplastic lymphoma kinase; ANG1, angiopoietin 1; BAD, BCL-2-associated agonist of cell death; CCND, cyclin D; CDK, cyclin-dependent kinase; CTLA4, cytotoxic T lymphocyte-associated antigen 4; EGFR, epidermal growth factor receptor; FGFR4, fibroblast growth factor receptor 4; FOXO1; forkhead box O1; GSK3, glycogen synthase kinase 3; HDAC, histone deacetylase; IGF1R, insulin-like growth factor 1 receptor; NICD, Notch intracellular domain; NF1, neurofibromin 1; PAX, paired box; PD1, programmed cell death protein 1; PDGFR, platelet-derived growth factor receptor; PLK1, Polo-like kinase 1; PTCH, Patched; RB1, retinoblastoma 1; RBPJ, recombination signal binding protein for immunoglobulin kJ region (also known as CSL); RHEB, RAS homologue enriched in brain; SHH, sonic hedgehog; SMO, Smoothened; TSC2, tuberin; VEGFR2, vascular endothelial growth factor receptor 2.
